Trifluoroacetic Acid

Trifluoroacetic Acid

SCHEMBL334563

N#CC1CCNCC1.O=C(O)C(F)(F)F

nearest known ligand 0.42

Full drug profile on Sugi Atlas →

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
GABRP O00591 1/20 0.39
GABRD O14764 1/20 0.39
GABRA1 P14867 1/20 0.39
TSHR P16473 1/20 0.39
GABRB1 P18505 1/20 0.39
GABRG2 P18507 1/20 0.39
GABRB3 P28472 1/20 0.39
GABRA5 P31644 1/20 0.39
GABRA3 P34903 1/20 0.39
GABRA2 P47869 1/20 0.39
GABRB2 P47870 1/20 0.39
GABRA4 P48169 1/20 0.39
GABRE P78334 1/20 0.39
PMP22 Q01453 1/20 0.39
GABRA6 Q16445 1/20 0.39
GABRG1 Q8N1C3 1/20 0.39
GABRG3 Q99928 1/20 0.39
GABRQ Q9UN88 1/20 0.39
KDM1A O60341 3/20 0.34
EPHX1 P07099 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Trifluoroacetic Acid SCHEMBL31601844 0.89 SLC6A1 (0.35) GABRPGABRDGABRA1TSHRGABRB1
Trifluoroacetic Acid SCHEMBL2379448 0.89 SLC6A1 (0.35) GABRPGABRDGABRA1TSHRGABRB1
Trifluoroacetic Acid SCHEMBL2378662 0.89 SLC6A1 (0.35) GABRPGABRDGABRA1TSHRGABRB1
Trifluoroacetic Acid SCHEMBL28132681 0.86 KDM1A (0.35) KDM1ADPP4DPP8
Pivalate SCHEMBL28484105 0.85 GABRP (0.39) GABRPGABRDGABRA1TSHRGABRB1
Trifluoroacetic Acid SCHEMBL3758972 0.81 TSHR (0.43) GABRPGABRDGABRA1TSHRGABRB1
Trifluoroacetic Acid SCHEMBL14743994 0.80 DPP4 (0.36) DPP4DPP8
Trifluoroacetic Acid SCHEMBL17500734 0.80 SLC6A2 (0.32) KDM1ADPP4DPP8
Trifluoroacetic Acid SCHEMBL2394605 0.79 SLC6A1 (0.42) TSHRDPP4DPP8CPN1CPB2
Trifluoroacetic Acid SCHEMBL2377040 0.79 SLC6A1 (0.42) TSHRDPP4DPP8CPN1CPB2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 22 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2025110815-A1 IMIDAZO [1,2-B] PYRIDAZINE-BASED NOVEL COMPOUND AS CDK INHIBITOR AND USE THEREOF 아이리드비엠에스 주식회사 2025-05-30 WO disclosed
CN-116057061-A USP7 inhibitors 首药控股(北京)股份有限公司 2023-05-02 CN disclosed
CN-115215883-A USP7 inhibitors 首药控股(北京)股份有限公司 2022-10-21 CN disclosed
CN-114907368-A USP7 inhibitors 首药控股(北京)股份有限公司 2022-08-16 CN disclosed
CN-114656479-A USP7 inhibitor 首药控股(北京)股份有限公司 2022-06-24 CN disclosed
CN-114539283-A USP7 inhibitor 首药控股(北京)股份有限公司 2022-05-27 CN disclosed
WO-2022048498-A1 USP7 INHIBITOR 首药控股(北京)股份有限公司 2022-03-10 WO disclosed
WO-2020243027-A1 COMPOUNDS, COMPOSITIONS, AND METHODS OF USE SAGE THERAPEUTICS, INC. (US) 2020-12-03 WO disclosed
CN-107207435-B Process for preparing 4-cyanopiperidine hydrochloride 拜耳作物科学股份公司 2020-05-19 CN disclosed
EP-3245190-B1 METHOD FOR PREPARING 4-CYANOPIPERIDINE HYDROCHLORIDE BAYER CROPSCIENCE AG (DE) 2018-12-26 EP disclosed
EP-3245190-A1 METHOD FOR PREPARING 4-CYANOPIPERIDINE HYDROCHLORIDE Bayer CropScience Aktiengesellschaft (DE) 2017-11-22 EP disclosed
CN-107207435-A Process for preparing 4-cyanopiperidine hydrochloride 拜耳作物科学股份公司 2017-09-26 CN disclosed
WO-2016113277-A1 METHOD FOR PREPARING 4-CYANOPIPERIDINE HYDROCHLORIDE BAYER CROPSCIENCE AKTIENGESELLSCHAFT (DE) 2016-07-21 WO disclosed
US-8097610-B2 Derivative having PPAR agonistic activity SHIONOGI & CO., LTD. (JP) 2012-01-17 US disclosed
US-7888374-B2 Inhibitors of c-jun N-terminal kinases ABBOTT LABORATORIES (US) 2011-02-15 US disclosed
US-20090286974-A1 Derivative having ppar agonistic activity SHIONOGI & CO., LTD. (JP) 2009-11-19 US disclosed
CN-101228127-A Novel Piperidine Derivatives BANYU PHARMA CO LTD (JP) 2008-07-23 CN disclosed
EP-1939189-A1 DERIVATIVE HAVING PPAR AGONISTIC ACTIVITY SHIONOGI & CO., LTD. (JP) 2008-07-02 EP disclosed
WO-2006083673-A2 PYRIDINE DERIVATIVES USEFUL AS INHIBITORS OF C-JUN N-TERMINAL KINASES ABBOTT LABORATORIES (US) 2006-08-10 WO disclosed
US-20060173050-A1 Inhibitors of c-Jun N-terminal kinases ABBVIE INC. 2006-08-03 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060173050-A1 Inhibitors of c-Jun N-terminal kinases MAPKAPK3, MAP3K3, MAPK3 GABRP 3681/4885GABRD 2449/4885GABRA1 4084/4885
US-20090286974-A1 Derivative having ppar agonistic activity PPARD, PPARA, PPARG GABRP 634/4885GABRD 398/4885GABRA1 594/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.